Literature DB >> 7218735

[Veno-occlusive syndrome with acute liver dystrophy following decarbazine therapy of malignant melanoma (author's transl)].

H Voigt, J Caselitz, M Jänner.   

Abstract

Case report about death due to veno-occlusive liver disease following Dacarbazine treatment: 9 years after surgical treatment of malignant melanoma of the trunk a 68-years old patient developed lymph node metastases in the right axilla, which were removed immediately by surgical excision. One month before the patient had undergone surgical treatment of empyema of the gallbladder: Cholecystectomy and appendectomy were performed, postoperative recovery was uncomplicated. On account of the second lymph node metastasis within nine months adjuvant treatment with Dacarbazine was agreed and started one month later. After having performed the first course of treatment without any hints to intolerance the patient suddenly exhibited severe shock symptoms on the fourth day of the second course. Clinically residual myocardial infarct or pulmonary embolism were assumed, but could not be verified. The patient delivered increasing hepatomegaly. A massive increase in transaminase values was noted. Hemostasiologic changes with decreased Quick value occurred. The patient died of cerebral hemorrhage five days after beginning the second Dacarbazine cycle. Autopsy findings were severe liver cell necroses as well as liver vein thromboses, no metastases of melanoma could be found. Hepatotoxicity of Dacarbazine and the mechanism of liver vein thrombosis are discussed with special regards to possible hemostasiologic changes and sensibilisation due to Dacarbazine and/or previous liver cell damage.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7218735     DOI: 10.1007/bf01476580

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  23 in total

1.  Effect of imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazeno) on immunity in patients with malignant melanoma.

Authors:  H W Bruckner; M B Mokyr; M S Mitchell
Journal:  Cancer Res       Date:  1974-01       Impact factor: 12.701

2.  [Photosensitization with DTIC therapy in metastatic malignant melanoma].

Authors:  R Bolling; S Meyer-Hamme; S Schauder
Journal:  Hautarzt       Date:  1980-11       Impact factor: 0.751

3.  [Obliterative disease of liver veins: clinical, diagnostic, therapeutic and pathogenetic aspects of Budd-Chiari syndrome (author's transl)].

Authors:  G H Bützow; A Burkhardt; D Novak; K Becker
Journal:  Dtsch Med Wochenschr       Date:  1976-02-27       Impact factor: 0.628

4.  Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group.

Authors:  R O Johnson; G Metter; W Wilson; G Hill; E Krementz
Journal:  Cancer Treat Rep       Date:  1976-02

5.  Hepatic veno-occlusive disease due to DTIC.

Authors:  R F Asbury; S N Rosenthal; M E Descalzi; R L Ratcliffe; J C Arseneau
Journal:  Cancer       Date:  1980-05-15       Impact factor: 6.860

6.  [Combined chemotherapy of metastasing melanoblastoma using ifosfamide and cis-platinum (II)-diamminodichloride (author's transl)].

Authors:  C G Schmidt; R Becher
Journal:  Dtsch Med Wochenschr       Date:  1979-06-15       Impact factor: 0.628

7.  Unusual obliterative disease of the hepatic veins in an infant.

Authors:  A Burkhardt; G Klöppel
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1977-09-28

8.  Hepatic failure in a patient treated with dacarbazine (DTIC) for malignant melanoma.

Authors:  P J Frosch; B M Czarnetzki; E Macher; E Grundmann; I Gottschalk
Journal:  J Cancer Res Clin Oncol       Date:  1979       Impact factor: 4.553

9.  Recurrent hepatitis following halothane exposures.

Authors:  W Schlippert; S Anuras
Journal:  Am J Med       Date:  1978-07       Impact factor: 4.965

10.  Veno-occlusive disease of the liver after chemotherapy of acute leukemia. Report of two cases.

Authors:  P F Griner; A Elbadawi; C H Packman
Journal:  Ann Intern Med       Date:  1976-11       Impact factor: 25.391

View more
  2 in total

Review 1.  Drug-induced liver injury: is it somehow foreseeable?

Authors:  Giovanni Tarantino; Matteo Nicola Dario Di Minno; Domenico Capone
Journal:  World J Gastroenterol       Date:  2009-06-21       Impact factor: 5.742

2.  Mechanisms of hepatotoxicity caused by dacarbazine in rats.

Authors:  R Paschke; M Heine; S Braun; K H Usadel
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.